Sinopharm Group Co (HKSE:01099) ROC % : 6.85% (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sinopharm Group Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 6.85%.

As of today (2024-12-15), Sinopharm Group Co's WACC % is 4.58%. Sinopharm Group Co's ROC % is 7.99% (calculated using TTM income statement data). Sinopharm Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Sinopharm Group Co ROC % Historical Data

The historical data trend for Sinopharm Group Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co ROC % Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC %

Get a 7-Day Free Trial

13.35

12.93

11.98

11.15

11.18

Sinopharm Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROC %	Get a 7-Day Free Trial															8.27	11.04	8.12	10.14	6.85

Sinopharm Group Co ROC % Calculation

Sinopharm Group Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	24366.067 * ( 1 - 23.07% )	/	( (168819.648	+	166407.904)	/ 2 )
=	18744.8153431	/	167613.776
=	11.18 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	407349.761	-	176862.757	-	( 61667.356	-	max(0, 262386.592	-	356685.808	+	61667.356	))
=	168819.648

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	419349.185	-	183148.251	-	( 69793.03	-	max(0, 264137.36	-	368423.12	+	69793.03	))
=	166407.904

Sinopharm Group Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	18069.112 * ( 1 - 22.34% )	/	( (166407.904	+	243517.498)	/ 2 )
=	14032.4723792	/	204962.701
=	6.85 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	419349.185	-	183148.251	-	( 69793.03	-	max(0, 264137.36	-	368423.12	+	69793.03	))
=	166407.904

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	462464.905	-	172298.281	-	( 46649.126	-	max(0, 304917.898	-	411630.206	+	46649.126	))
=	243517.498

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

Sinopharm Group Co (HKSE:01099) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sinopharm Group Co's WACC % is 4.58%. Sinopharm Group Co's ROC % is 7.99% (calculated using TTM income statement data). Sinopharm Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Sinopharm Group Co ROC % Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Lazard Asset Management Llc	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Fmr Llc	2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines